Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain

Pharmacological Research

Volumn 87, Issue , 2014, Pages 87-93

  Moreno Sanz, Guillermo ^a   Barrera, Borja ^b   Armirotti, Andrea ^c   Bertozzi, Sine M ^c   Scarpelli, Rita ^c   Bandiera, Tiziano ^c   Prieto, Julio G ^b   Duranti, Andrea ^d   Tarzia, Giorgio ^d   Merino, Gracia ^b   Piomelli, Daniele ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LEÓN   (Spain)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

Author keywords

Abcb1 P gp; Abcg2 Bcrp; ATP binding cassette transporters; Blood brain barrier; FAAH inhibitor; Fatty acid amidohydrolase (FAAH)

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYL 6 HYDROXYBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; URB 937; ABC TRANSPORTER; AMIDASE; CANNABINOID; CARBAMIC ACID DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; URB937;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGEN BOND; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; DOG; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM;

AMIDOHYDROLASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; CANNABINOIDS; CARBAMATES; DOGS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, KNOCKOUT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904187685     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.06.004     Document Type: Article

References (31)

1. R. Cecchelli, V. Berezowski, S. Lundquist, M. Culot, M. Renftel, and M.P. Dehouck et al. Modelling of the blood-brain barrier in drug discovery and development Nat Rev Drug Discov 6 8 2007 650 661 (Pubitemid 47202487)
2. S. Agarwal, A.M. Hartz, W.F. Elmquist, and B. Bauer Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up Curr Pharm Des 17 26 2011 2793 2802
3. C. Chaves, R. Shawahna, A. Jacob, J.M. Scherrmann, and X. Decleves Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration Curr Pharm Des 20 10 2014 1450 1462
4. J. Konig, F. Muller, and M.F. Fromm Transporters and drug-drug interactions: important determinants of drug disposition and effects Pharmacol Rev 65 3 2013 944 966
5. F.J. Sharom ABC multidrug transporters: structure, function and role in chemoresistance Pharmacogenomics 9 1 2008 105 127 (Pubitemid 351560534)
6. F. Lecerf-Schmidt, B. Peres, G. Valdameri, C. Gauthier, E. Winter, and L. Payen et al. ABCG2: recent discovery of potent and highly selective inhibitors Future Med Chem 5 9 2013 1037 1045
7. M. Falasca, and K.J. Linton Investigational ABC transporter inhibitors Expert Opin Investig Drugs 21 5 2012 657 666
8. D.A. Gutmann, A. Ward, I.L. Urbatsch, G. Chang, and H.W. van Veen Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1 Trends Biochem Sci 35 1 2010 36 42
9. M.F. Rosenberg, Z. Bikadi, J. Chan, X. Liu, Z. Ni, and X. Cai et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone Structure 18 4 2010 482 493
10. Z. Ni, Z. Bikadi, M.F. Rosenberg, and Q. Mao Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) Curr Drug Metab 11 7 2010 603 617
11. A.I. Alvarez, M. Perez, J.G. Prieto, A.J. Molina, R. Real, and G. Merino Fluoroquinolone efflux mediated by ABC transporters J Pharm Sci 97 9 2008 3483 3493
12. J.R. Clapper, G. Moreno-Sanz, R. Russo, A. Guijarro, F. Vacondio, and A. Duranti et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism Nat Neurosci 13 10 2010 1265 1270
13. G. Moreno-Sanz, B. Barrera, A. Guijarro, I. d'Elia, J.A. Otero, and A.I. Alvarez et al. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system Pharmacol Res 64 4 2011 359 363
14. J.R. Clapper, F. Vacondio, A.R. King, A. Duranti, A. Tontini, and C. Silva et al. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo ChemMedChem 4 9 2009 1505 1513
15. G. Moreno-Sanz, A. Duranti, L. Melzig, C. Fiorelli, G.F. Ruda, and G. Colombano et al. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors J Med Chem 56 14 2013 5917 5930
16. M. Yoshikawa, Y. Ikegami, S. Hayasaka, K. Ishii, A. Ito, and K. Sano et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells Int J Cancer 110 6 2004 921 927 (Pubitemid 38758521)
17. E.E. Bram, Y. Adar, N. Mesika, M. Sabisz, A. Skladanowski, and Y.G. Assaraf Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2 Mol Pharmacol 75 5 2009 1149 1159
18. A. Gonzalez-Sarrias, V. Miguel, G. Merino, R. Lucas, J.C. Morales, and F. Tomas-Barberan et al. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP) J Agric Food Chem 61 18 2013 4352 4359
19. B. Poller, D. Iusuf, R.W. Sparidans, E. Wagenaar, J.H. Beijnen, and A.H. Schinkel Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics Drug Metab Dispos 39 5 2011 729 735
20. S.C. Tang, N. de Vries, R.W. Sparidans, E. Wagenaar, J.H. Beijnen, and A.H. Schinkel Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib J Pharmacol Exp Ther 346 3 2013 486 494
21. S. Shityakov, W. Neuhaus, T. Dandekar, and C. Forster Analysing molecular polar surface descriptors to predict blood-brain barrier permeation Int J Comput Biol Drug Des 6 1-2 2013 146 156
22. A. Pal, D. Mehn, E. Molnar, S. Gedey, P. Meszaros, and T. Nagy et al. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2 J Pharmacol Exp Ther 321 3 2007 1085 1094 (Pubitemid 46762703)
23. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, and J.H. Schellens et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J Natl Cancer Inst 92 20 2000 1651 1656
24. P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, and J.W. Jonker et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine, and transport of cimetidine J Pharmacol Exp Ther 312 1 2005 144 152 (Pubitemid 40096463)
25. G. Merino, J.W. Jonker, E. Wagenaar, M.M. Pulido, A.J. Molina, and A.I. Alvarez et al. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2) Drug Metab Dispos 33 5 2005 614 618 (Pubitemid 40593873)
26. M.T. Huisman, A.A. Chhatta, O. van Tellingen, J.H. Beijnen, and A.H. Schinkel MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid Int J Cancer 116 5 2005 824 829 (Pubitemid 41099717)
27. J. Bakhsheshian, M.D. Hall, R.W. Robey, M.A. Herrmann, J.Q. Chen, and S.E. Bates et al. Overlapping substrate and inhibitor specificity of human and murine ABCG2 Drug Metab Dispos 41 10 2013 1805 1812
28. D.A. Smith Evolution of ADME science: where else can modeling and simulation contribute? Mol Pharm 10 4 2013 1162 1170
29. S. Agarwal, and W.F. Elmquist Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance Mol Pharm 9 3 2012 678 684
30. H. Kodaira, H. Kusuhara, J. Ushiki, E. Fuse, and Y. Sugiyama Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J Pharmacol Exp Ther 333 3 2010 788 796
31. F. Lin, S. Marchetti, D. Pluim, D. Iusuf, R. Mazzanti, and J.H. Schellens et al. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues Clin Cancer Res 19 8 2013 2084 2095